Wockhardt to market Cefotaxime injection in US

Wockhardt today said it has received approval from USFDA for marketing antibiotic Cefotaxime sodium injection in the US market.

The company informed the Bombay Stock Exchange that it received the approval for marketing Cefotaxime sodium in dosages of 1 gm. Cefotaxime sodium is the generic version of Sanofi Aventis Claforan injection and is used in treating a wide variety of infections.

"This is our second approval for sterile cephalosporins, and our sixth approval in the last eight months. The rapid build-up of portfolio is helping us make our presence felt in the US - the world's largest pharmaceutical market," the company's Chairman Habil Khorakiwala said.

Wockhardt said its US subsidiary, Wockhardt USA Inc, would launch the antibiotic in the US market within the next few weeks. The company currently markets 14 products in the US.

Cefotaxime sodium is manufactured at the company's USFDA certified facility at Ankleshwar and the injection is manufactured at the sterile formulation plant at Waluj.